Oxford BioDynamics develops and commercializes epigenetic-based diagnostic tests built on its proprietary EpiSwitch 3D genomics platform. Its flagship product, the EpiSwitch Prostate Screening (PSE) Test, saw monthly orders rise from fewer than 100 tests in September 2024 to 215 tests in September 2025, and the company is targeting 500 monthly tests within the next 12 months. The firm is also advancing the EpiSwitch CiRT cancer test toward inclusion in National Comprehensive Cancer Network guidelines and is working with Google Cloud to monetize its 3D genomics data platform. Revenue figures were not disclosed, but management highlighted month-over-month sales growth for the PSE test. Future plans include pursuing additional business development opportunities and non-dilutive funding through potential licensing or distribution agreements. The recently announced equity raise is intended to provide the working capital needed to execute these growth initiatives.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025